A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge
Open Access
- 31 August 2024
- journal article
- research article
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (08) , 1281-1290
Abstract
Introduction: Rabies is a fatal infectious disease, that poses a major public health threat in developing countries. With an annual death toll of approximately 59,000, more than half of which are children, an urgent need exists for a safe, affordable, and effective preventive measure against rabies virus infection. Methodology: A recombinant rabies vaccine called Ad5-dRVG was constructed by introducing two copies of the rabies virus glycoprotein into a human adenoviral vector. Virus-neutralizing assays and virus challenge experiments were employed to evaluate the Ad5-dRVG vaccine. Results: Our findings demonstrate that a single dose of Ad5-dRVG, administered either intramuscularly or orally, elicited significantly stronger immune responses than Ad5-RVG. Moreover, both vaccines provided complete protection in mice. Notably, the vaccine exhibited remarkable efficacy even at low doses, suggesting potential cost reduction in production. Conclusions: The development of the Ad5-dRVG recombinant rabies vaccine represents a significant advancement in rabies prevention. Its enhanced immunogenicity, demonstrated efficacy and potential cost savings make it a promising candidate for widespread use.Keywords
This publication has 50 references indexed in Scilit:
- Rabies control in high-burden countries: role of universal pre-exposure immunizationThe Lancet Regional Health - Southeast Asia, 2023
- Global burden of rabies in 204 countries and territories, from 1990 to 2019: results from the Global Burden of Disease Study 2019International Journal of Infectious Diseases, 2022
- Rabies VirusTrends in Microbiology, 2018
- The lyssavirus host-specificity conundrum — rabies virus — the exception not the ruleCurrent Opinion in Virology, 2018
- Rabies virus vaccines: Is there a need for a pan-lyssavirus vaccine?Vaccine, 2012
- Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB®) in target and non-target speciesVaccine, 2009
- Poxvirus-vectored vaccines for rabies—A reviewVaccine, 2009
- Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai childrenVaccine, 2006
- Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccineVaccine, 2005
- Evaluation of Accuracy and Precision of Adenovirus Absorptivity at 260 nm under Conditions of Complete DNA DisruptionVirology, 2002